# Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

> **NCT04530552** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Localized Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Apalutamide
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04530552
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-23
- **Primary completion:** 2024-11-06
- **Final completion:** 2027-01-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530552, "Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04530552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*